happens every time on these offerings. To make money, you got to be patient, take advantage of opportunities, kije this one. Still the same company as yesterday, only difference is number of shares. Not real sure on a price adjusted basis what it should be based on previous number plus new shares, but I bet it is way above .53, where some people are selling. glta
The dilution and the fail in trials are the main dangers a holder of a stage development bio company can face, the first can heart badly the share price for a short time, the second for long long time...Now INO have to announce good results to repay its holders.